title: [Gemcitabine in combination with S-1 or UFT in patients with advanced pancreatic cancer].
abstract: The present retrospective study aimed to evaluate the anti-tumor activity and toxicity of combination chemotherapy with gemcitabine (GEM) and oral S-1 or UFT in patients with advanced or metastatic pancreatic cancer. Ninety-four patients received chemotherapy. Among them, sixty-three were treated with GEM alone, twenty-two with UFT and GEM (UFT/GEM), and nine with S-1 and GEM(S-1/GEM). The median survival time was 8.7 months with GEM, 7.3 months with UFT/GEM, and 23.3 months with S-1/GEM. The overall response rate was 11.1%, 10.0%, and 22.2%, respectively. The 1-year survival rate was 29.5%, 36.4%, and 85.7%, respectively. Although the treatment-related adverse effects were not infrequent in patients treated with S-1/GEM, they were moderate in intensity. The combination chemotherapy with S-1/GEM was well tolerated and yielded a high response rate in patients with pancreatic cancer.
authors.affiliation: Dept. of Gastroenterology and Hematology/Oncology, Asahikawa Medical College.
authors.forename: Junpei
authors.initials: J
authors.lastname: Sasajima
authors.forename: Satoshi
authors.initials: S
authors.lastname: Tanno
authors.forename: Kazuya
authors.initials: K
authors.lastname: Koizumi
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Nakano
authors.forename: Atsuya
authors.initials: A
authors.lastname: Habiro
authors.forename: Atsushi
authors.initials: A
authors.lastname: Chiba
authors.forename: Tsuneshi
authors.initials: T
authors.lastname: Fujii
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Sugiyama
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Nakamura
authors.forename: Tomoya
authors.initials: T
authors.lastname: Nishikawa
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Mizukami
authors.forename: Toshikatsu
authors.initials: T
authors.lastname: Okumura
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kohgo
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies; D015996:Survival Rate; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*; D014498:Uracil / Q000009:adverse effects / Q000627:therapeutic use; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D014498:Uracil; D010094:Oxonic Acid; D000093542:Gemcitabine